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Microbial products influence immunity after allogeneic hematopoietic stem cell trans-
plantation (allo-SCT). In this context, the role of cathepsin E (Ctse), an aspartate protease 
known to cleave bacterial peptides for antigen presentation in dendritic cells (DCs), has 
not been studied. During experimental acute graft-versus-host disease (GVHD), we found 
infiltration by Ctse-positive immune cells leading to higher Ctse RNA- and protein levels 
in target organs. In Ctse-deficient allo-SCT recipients, we found ameliorated GVHD, 
improved survival, and lower numbers of tissue-infiltrating DCs. Donor T cell proliferation 
was not different in Ctse-deficient vs. wild-type allo-SCT recipients in MHC-matched 
and MHC-mismatched models. Furthermore, Ctse-deficient DCs had an intact ability to 
induce allogeneic T cell proliferation, suggesting that its role in antigen presentation may 
not be the main mechanism how Ctse impacts GVHD. We found that Ctse deficiency 
significantly decreases DC motility in  vivo, reduces adhesion to extracellular matrix 
(ECM), and diminishes invasion through ECM. We conclude that Ctse has a previously 
unrecognized role in regulating DC motility that possibly contributes to reduced DC 
counts and ameliorated inflammation in GVHD target organs of Ctse-deficient allo-SCT 
recipients. However, our data do not provide definite proof that the observed effect of 
Ctse−/− deficiency is exclusively mediated by DCs. A contribution of Ctse−/−-mediated 
functions in other recipient cell types, e.g., macrophages, cannot be excluded.
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inTrODUcTiOn
The biggest threat for patients receiving a potentially life-saving allogeneic hematopoietic stem cell 
transplantation (allo-SCT) is the development of severe graft-versus-host disease (GVHD). The con-
sequences of GVHD are organ damages, mainly in liver, intestines, and skin, leading to substantial 
morbidity and mortality. Recent research identified important mechanisms regarding the induction 
of GVHD through the interplay of microbial molecules and innate immunity, thus opening a new 
area for future therapeutic approaches (1–5).
Cathepsin E (Ctse) is an aspartic endopeptidase belonging to the cathepsin family of proteases. 
Ctse is mainly expressed and active in antigen-presenting cells of the immune system, such as den-
dritic cells (DCs) and macrophages (6–8). The main known common function of cathepsin proteases 
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is to liberate peptide epitopes for antigen presentation (9, 10). 
Ctse was shown to be involved in antigen presentation of bacterial 
peptides in DCs, and it may also be important for the presentation 
of allogeneic peptides on MHC class II molecules (11–13). Recent 
studies demonstrated an increase in Ctse protein expression or 
enzymatic activity in patients suffering from Parkinson disease 
(14) or Helicobacter pylori infections (15). Ctse overexpression 
has been associated with several types of cancer (16–21) and has 
been used as a predictive biomarker in patients with malignant 
diseases (22–24). The role of Ctse for the pathophysiology of 
GVHD has not been studied experimentally.
To be able to analyze the impact of Ctse in  vivo, we have 
previously created Ctse–null mice, which have a normal 
phenotype (25). OVA-antigen processing and presentation by 
DCs showed no difference in Ctse+/+ and Ctse−/− mice in  vivo 
under non-inflammatory conditions. In experimental models 
of allergic airway inflammation, we found that Ctse deletion 
results in a reduced inflammatory response, marked by impaired 
lymphocyte infiltration into lungs in comparison to wild-type 
(WT) littermates (25). In the current study, we examined the 
role of Ctse during GVHD after allo-SCT and its influence on 
DC function.
MaTerials (Or sUBJecTs) anD 
MeThODs
Mice
Female C57BL/6 (H2b), 129S2/SvPasCrl (H2b), and B6D2F1 
(H2b/d), female and male LP/J (H2b) mice (10–12 weeks old) were 
purchased from Charles River Laboratories (Sulzfeld, Germany) 
and Jackson Laboratory (Bar Harbor, ME, USA). Female Ctse−/− 
and Ctse+/+ mice (25) were bred by and obtained from the central 
animal unit of the Charité University Medicine. Mice had access 
to food and water ad libitum. The Regional Ethics Committee for 
Animal Research (State Office of Health and Social Affairs Berlin) 
approved all animal experiments. Number: G0118/13. Dr. Penack 
and Dr. Mengwasser. Title: Ctse in allo-HSCT.
conditioning regimen
Busulfan (Sigma-Aldrich, St. Louis, MO, USA) was dissolved 
in DMSO (40  mg/ml) and cyclophosphamide monohydrate 
(Sigma-Aldrich) in sterile water (10  mg/ml). Female C57BL/6 
received IP doses of busulfan (20 mg/kg/day) for 4 days, followed 
by cyclophosphamide (100 mg/kg/day) for 2 days. Days -2 and -1 
prior to HSCT were resting days.
Bone Marrow (BM) Transplantation (stem 
cell Transplantation, scT)
We have recently described a chemotherapy-based MHC-
matched miHA-mismatched murine GVHD model, which may 
better resemble human GVHD as compared with traditional 
radiation-based MHC-mismatched models (26). In this model, 
C57BL/6 mice are used as allo-SCT recipients. Therefore, we 
were able to use this specific model for all studies investigating 
Ctse−/− on the recipient side. For investigation of Ctse−/− on 
the donor side, we had to use an alternative model, because no 
reliable chemotherapy-based miHA-mismatched models exist 
with C57BL/6 mice on the donor side. We opted for the next 
best situation and used a haploidentical model for testing of 
Ctse−/− on the donor side. Recipient C57BL/6 mice were injected 
i.v. with 1.5 × 107 BM cells and 2 × 106 splenic T cells from LP/J 
(allogeneic) and C57BL/6 (syngeneic) donor mice on day 0. 
BM from the tibia and femur was flushed with isolation buffer 
(PBS/2% FCS/1 mM EDTA) and single-cell suspension was pre-
pared by gently passing through a 23G needle and over a 70 μm 
cell strainer (BD Biosciences, San Jose, CA, USA). Splenocytes 
were passed through a 40 μm cell strainer. Erythrocytes were 
lysed with ammonium chloride buffer (Sigma-Aldrich). Splenic 
T cell was obtained using the mouse Pan T Cell Isolation Kit II 
(Miltenyi Biotec, Bergisch Gladbach, Germany) according to 
manufacturer’s instructions. T cell purity was analyzed by CD3 
staining and FACS analysis.
gVhD Monitoring
Mice were individually scored twice a week for five clinical 
parameters (posture, activity, fur, skin, and weight loss) on a scale 
from 0 to 2. Clinical GVHD score was assessed by summation of 
these parameters. Survival was monitored daily.
Tumor experiments
C57BL/6 mice received 1 × 106 EL4 (C57BL/6) T cell lymphoma 
tumor cells stably expressing firefly luciferase intravenously. 
Tumor growth was measured by bioluminescence imaging. 3 mg/
mouse d-luciferin (Xenogen, Alameda, CA, USA) was injected 
i.p., mice were anesthetized and placed in an IVIS 200 system. 
Average radiance (p/s/cm2/sr) was determined using the Living 
Image 3.1 software (PerkinElmer, Waltham, MA, USA).
Facs analysis
Peripheral blood was lysed for 10 min with ammonium chloride. 
BM, spleen, lymph node, and thymus were prepared consistent 
to the BMT Protocol. Single-cell suspensions were washed two 
times, collected in MACS buffer (PBS/0.5 mM EDTA/0.5% BSA), 
and stained for 20  min at 4°C with rat anti-mouse antibodies 
from BD Biosciences. Antibodies used are anti-Ly9.1-PE (30C7), 
APC-conjugated anti-CD8a (53-6.7), PerCP-Cy5.5-conjugated 
anti-CD45R/B220 (RA3-6B2), FITC-conjugated anti-H2kb 
(AF6-88.5), PE-Cy7-conjugated anti-CD4 (RM4-5), anti-CD11c 
(HL3), APC-Cy7-conjugated anti-CD3e (145-2C11), and 
PerCPCy5.5-conjugated anti-mouse CD86 (GL-1). Samples were 
analyzed using a BD FACSCanto II (BD Biosciences) and FlowJo 
7.6.5 Software (Tree Star Inc., Ashland, OR, USA).
histology
Tissue samples were harvested and cryo-embedded in Tissue-
Tek optimum cutting temperature compound (Sakura Finetek, 
Alphen aan den Rijn, Netherlands). Cryosections (5 μm) were 
acetone fixed at −20°C. Histopathological score was assessed 
on H&E-stained sections after Lerner criteria (27) and grade of 
liver inflammation [slight (1) or marked (2) portal/venous and 
marked lobular (3) inflammation]. Sections for analysis of lym-
phocyte infiltration were blocked by PBS/3% BSA/5% FCS and 
stained over night at 4°C with primary rat anti-mouse antibodies 
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against, CD11c (HL3), CD4 (H129.19), and CD8a (53-6.7) from 
BD Biosciences. Binding was visualized with secondary donkey 
anti-rat antibody conjugated with Alexa Fluor 488 or Cy3 (Life 
Technologies) and nuclear counterstain was performed using 
4,6-diamidino-2-phenylindole (Sigma-Aldrich). Five sections 
per sample were investigated with a Motic BA410 epifluorescence 
microscope (Motic, Hong Kong) and quantification was assessed 
by calculating CD11c+, CD4+, or CD8+ area against total liver 
parenchyma or colon mucosal area with a predetermined thresh-
old using Fiji Software (http://fiji.sc/Fiji).
image acquisition
Fluorescence and bright-field images were taken using a Motic 
BA410 microscope with a Moticam Pro 285B and the Motic 
Images Plus 2.0 software. The used objectives were Plan Fluar 
10×/0.30, 20×/0.50, and 40×/0.75. Adobe Photoshop CS6 was 
used for image processing.
anti-Mouse ctse Polyclonal antibody 
generation
The following peptide sequence of mouse Ctse: 
SLITGPPDKIKQLQE, which represents amino acids 286–300 
of the mouse Ctse protein was chosen for immunization. 
Immunization of rabbits was done with the specific mouse Ctse 
peptide bound to a protein carrier (KLH) for 6 months, boosting 
once per month. Rabbit serum was isolated from positively tested 
animals, and the IgG fraction was purified.
Dc generation
Dendritic cells (Ctse+/+ and Ctse−/−) were generated from fresh 
isolated BM cells grew in CellGro DC medium (CellGenix) 
containing 10% FCS (Pan Biotech), IL-4 (10 ng/ml) (R&D), and 
GM-CSF (10 ng/ml) (GIBCO). Medium was changed on days 2 
and 4. On the seventh day, cells were analyzed by flow cytometry 
using the markers CD11c, F4/80, CD14, MHCII, CD11b, CD80, 
CD86, CD45, CD3, and CD19.
FiTc sensitization experiment
Mice (Ctse+/+, Ctse+/−, and Ctse−/−) were anesthetized with 
Ketamin/Rompun (1:1). FITC (SIGMA) (10  mg/ml) was dis-
solved in equal volumes of acetone/dibutylphthalate (1:1) and 
applied with a pipet tip to the ear skin and the dorsal skin of 
Ctse+/+ and Ctse−/− mice. Lymph nodes (inguinal, mandibulares, 
retropharyngeus lateralis, axillaris, accesorius, and brachial) 
were removed 24 h later. Cell suspensions of total lymph nodes 
were prepared by straining the nodes through a nylon mesh filter 
(70 μm) and analyzed by flow cytometry. CD11c was used as 
DC marker. A total of 50,000 cells were counted and the relative 
migration of DCs was calculated by dividing the CD11c+ DCs 
through the sum of FITC+CD11c+ DCs and CD11c+ DCs.
adhesion assay
The adhesion of DCs (Ctse+/+ and Ctse−/−) was measured with 
the xCELLigence system (Roche) using E-plates (16 wells). Cells 
adhere to the bottom of the wells and lead to a change in the 
electrical impedance, which is measured by gold microelectrodes. 
The more cells adhere the higher increases the electrical imped-
ance, which is displayed as Cell Index. The E-plates were coated 
with different substrates: collagen I 1.73 mg/ml (BD Biosciences), 
fibronectin 10 μg/ml (Sigma), and matrigel 9 mg/ml (Cultrex). A 
total of 50,000 DCs were activated with LPS in the well (4 μg/ml). 
Cell adhesion was measured within 2 h.
invasion assay
Invasion of Ctse+/+ and Ctse−/− DCs was investigated with 
xCELLigence system (Roche). Microporous membrane (3 μm) 
in CIM-plates was either coated with a 1-mm thick layer of 
collagen I 1.73 mg/ml (BD Biosciences) or matrigel 9 mg/ml 
(Cultrex). The gold microelectrodes are attached below the 
membranes. A total of 80,000 DCs (Ctse+/+ and Ctse−/−) were 
seeded on coated membranes in the upper compartment in 
the presence of LPS (4  μg/ml). In the lower compartment, 
medium with chemokines CCL21 (500  ng/ml) and CCL19 
(500  ng/ml), both acting as CCR7 ligands, was present as a 
chemoattractant.
In Vivo T cell Proliferation assay
C57BL/6 Ctse−/− or C57BL/6 WT littermates were conditioned 
with chemotherapy as described above. CD3+ lymphocytes were 
isolated from spleens of either Balb/C or 129/J mice using mouse 
Pan T cell isolation Kit II (Miltenyi Biotec, Bergisch Gladbach, 
Germany) according to manufacturer’s instructions. Cells were 
loaded with CFSE (carboxyfluorescein diacetate, succinimidyl 
ester) at a final concentration of 2.5 μmol for 8 min at 37°C in 
10% FCS/PBS. 5 ×  106 CFSE-loaded CD3+ cells were injected 
i.v. into the tail vein at day 0. Ninety-six hours later, mice were 
sacrificed, spleens and lymph nodes were taken and cells were 
isolated. After staining with the appropriate donor marker (H2kd 
for Balb/C and Ly9 for 129/J), cell samples were analyzed using 
a BD FACSCanto II (BD Biosciences) and FlowJo 7.6.5 Software 
(Tree Star Inc., Ashland, OR, USA).
Mixed leukocyte reaction (Mlr)
Dendritic cells were isolated from spleen of C57BL/6 Ctse−/− and 
WT mice using a CD11c+ isolation kit and splenic T cells from 
LP/J mice were obtained using the mouse Pan T cell isolation Kit 
II (Miltenyi Biotec, Bergisch Gladbach, Germany) according to 
the manufacturer’s instructions. DCs were treated with 100 ng/
ml LPS or left untreated for 4 h. T-cells were loaded with CFSE 
(5-(and-6)-carboxyfluorescein diacetate, succinimidyl ester, 
Thermo Fisher). 2.5 × 104 DCs (activators) and 2.5 × 105 T-cell 
(responders) were put together for 96 h in an incubator at 37°C 
and 5% CO2. FACS analysis was done measuring total cell counts 
positive for CFSE and CD3. Proliferating cells are determined as 
cells, showing less CFSE load compared to control samples with 
only CFSE-loaded T-cells.
real-time Pcr
RNA and cDNA were obtained using the RNeasy Mini Kit 
(QIAGEN, Venlo, Netherlands) and the QuantiTect Reverse 
Transcription Kit (QIAGEN) after manufacturer’s instructions. 
Real-time PCR amplification reaction (50°C for 2  min, 95°C 
for 10  min, 49 cycles of 95°C for 10  s, 60°C for 1  min) was 
FigUre 1 | cathepsin e (ctse) expression is increased in target 
organs during graft-versus-host disease (gVhD). (a,B) Ctse mRNA 
expression assessed by qPCR in colon and liver during acute GVHD 
[aGVHD, allogeneic stem cell transplantation; allogeneic hematopoietic stem 
cell transplantation (allo-SCT)], and syngeneic transplanted control animals 
(no GVHD, syn-SCT) at day +15 after allo-SCT in the LP/J→C57BL/6 model. 
Ctse expression is shown relative to the no GVHD control group. n = 5 per 
group (c,D) Ctse protein expression is elevated in immune cell infiltrates in 
the colon during acute GVHD (aGVHD) compared to syn-SCT recipients 
without GVHD (no GVHD). Ctse expression is shown in green, CD11c is 
shown in red, nuclear counterstain with DAPI is shown in blue, Ctse-
expressing cells are highlighted with white arrows, same arrow positions are 
shown in the CD11c staining, illustrating that Ctse-positive cells are also 
CD11c+. Dotted line marks the border of the lamina propria to the lamina 
muscularis mucosae. Fluorescence images were taken using a Motic BA410 
microscope with a Moticam Pro 285B and the Motic Images Plus 2.0 
software. The used objective was a Plan Fluar 40×/0.75. Error bars indicate 
mean ± SEM, p-values in (a,B) were calculated using a double-sided 
Student’s t-test. Bar = 50 μm.
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performed on DNA Engine Opticon (BioRad, Hercules, CA, 
USA) using the TaqMan Gene Expression Master Mix (Life 
Technologies) and primers and probes (BioTez GmbH, Berlin, 
Germany) designed with the Primer Express 1.5 software (Life 
Technologies). Data were analyzed with the Opticon Monitor 
3.1 analysis software (BioRad) and the comparative CT method 
(ΔΔCT method).
statistics
Survival data were analyzed using the Kaplan–Meier method 
and compared with the Mantel–Cox log-rank test. For statisti-
cal analysis of all other data, rank sum tests were used, unless 
indicated otherwise. Values are presented as mean ± SEM. Values 
of p ≤ 0.05 were considered statistically significant. All statisti-
cal analyses were performed using GraphPad Prism software 
(GraphPad Software Inc., La Jolla, CA, USA).
resUlTs
ctse is Overexpressed in Target Organs 
during acute gVhD
First, we analyzed the expression profile of Ctse in target organs 
during acute GVHD in the murine MHC-matched, miHA-
mismatched LP/J→C57BL/6 (B6) allo-SCT model (26). Using 
qPCR and the comparative ΔΔCT method, we found a significant 
increase in Ctse mRNA levels in allo-SCT recipients with GVHD 
(aGVHD) relative to syngeneic (no GVHD) SCT recipients 
without GVHD in colon (mean: 5.58-fold increase in aGVHD 
vs. no GVHD, p =  0.003) and liver (mean: 3.87-fold increase 
in aGVHD vs. no GVHD, p = 0.045) at day +15 after allo-SCT 
(Figures 1A,B). Of note, the mean absolute mRNA expression 
level of Ctse in colon was more than 10 times higher as compared 
with liver (data not shown). In our hands, no commercially avail-
able antibody against Ctse worked in histology. Therefore, we 
produced a polyclonal rabbit anti-murine Ctse antibody choos-
ing a different mouse Ctse peptide epitope for immunization as 
described in the Section “Materials (or subjects) and Methods.” 
We checked the antibody for its specificity using Ctse KO and 
WT tissues in immunofluorescence, obtaining no staining in Ctse 
KO tissues. Using this antibody in immunofluorescence analysis 
of cryosections, we confirmed that mRNA expression correlated 
with protein levels. In liver, protein expression was nearly unde-
tectable, reflecting the results of the low mRNA expression level. 
Ctse protein expression was specifically increased in CD11c+ 
immune cell infiltrates in the colon in allo-SCT recipients 
(Figure 1C) during acute GVHD, but not in syn-SCT recipients 
(Figure 1D).
ctse Deficiency in Donor BM cells and 
Donor T cells Does not affect the 
Development of gVhD
To investigate the role of Ctse in regulating GVHD, we first 
investigated the effect of Ctse deficiency of allo-SCT donors on 
the development of GVHD. We used the haploidentical allo-SCT 
model C57BL/6 (H2b)→B6D2F1 (H2b/d). After chemotherapy 
with busulfan and cyclophosphamide, recipients received T 
cell-depleted BM (TCD-BM) and GVHD was induced by the 
addition of donor splenic T cells to the allograft. We used Ctse−/− 
donors and WT littermate donors as the source for TCD-BM or 
T cells. We did not detect significant differences in lethal GVHD 
between the two different groups (Figure 2A). Furthermore, we 
did not detect differences in clinical GVHD scores in allo-SCT 
FigUre 2 | lethal graft-versus-host disease (gVhD) is reduced in cathepsin e (ctse)-deficient allogeneic hematopoietic stem cell transplantation 
recipients. (a,B) No significant differences were observed when wild-type (WT) and Ctse−/− (Ctse KO) C57Bl/6 were used as donors in the C57BL/6→B6D2F1 
model. (c,D) WT and Ctse−/− C57Bl/6 mice were used as recipients in the LP/J→C57BL/6 model. (a,c) Survival curves. (B,D) Cumulated clinical score (posture, 
movement, fur, skin, weight; single score: 0–2, max. score: 10). Error bars indicate mean ± SEM, p-values in (a,c) were calculated using a log-rank (Mantel–Cox) 
test, ***p < 0.001.
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recipients between the Ctse−/− donor group and WT donor group 
(Figure 2B).
ctse−/− allo-scT recipients have reduced 
lethal acute gVhD
Next, we used the LP/J (H2b)→C57BL/6 (H2b) model to inves-
tigate Ctse deficiency in allo-SCT recipients (26). We found sig-
nificantly less lethal GVHD in B6 Ctse−/− allo-SCT recipients as 
compared to B6 WT littermate allo-SCT recipients (Figure 2C). 
We performed investigator-blinded scoring for clinical GVHD 
symptoms and found significantly reduced clinical GVHD scores 
in Ctse−/− allo-SCT recipients vs. WT littermate allo-SCT recipi-
ents (Figure 2D). To analyze target organ GVHD, we performed 
histopathological analyses and found less GVHD in the liver and 
a trend toward less GVHD in colon (Figures  3A,B,D,E). The 
numbers of tissue-infiltrating alloreactive T-lymphocytes were 
reduced in Ctse−/− allo-SCT recipients in GVHD target organs 
colon and liver (Figures  3C,F) at peak GVHD development 
on day +16 following BMT, demonstrating less GVHD-related 
target organ inflammation.
analyses of systemic inflammation during 
gVhD in ctse-Deficient vs. WT allo-scT 
recipients
To analyze the impact of Ctse deficiency on engraftment and 
on systemic inflammation during GVHD, we sacrificed Ctse−/− 
allo-SCT recipients and WT allo-SCT recipients in the LP/J 
(H2b)→C57BL/6 (H2b) model at day +16 after allo-SCT. We 
harvested blood, BM, thymus, spleen, and peripheral lymph 
nodes for flow cytometric analyses. In these experiments, we 
found similar numbers for donor chimerism and for most lym-
phoid and myeloid cell populations in the blood, BM, thymus, 
spleen, and peripheral lymph nodes of Ctse-deficient vs. WT 
allo-SCT recipients (Figures S1–3 in Supplementary Material). 
Of note, we found no significant differences of donor T cell num-
bers in blood and spleen (Figures S2 and S3 in Supplementary 
Material). However, in lymph nodes, we found significantly 
reduced CD8+ T cell counts in Ctse-deficient allo-SCT recipi-
ents vs. WT allo-SCT recipients (Figures 4A,B). The number 
of donor CD8+ T cells were reduced (Figure 4B), leading to an 
overall reduction of total CD8+ T cells (Figure 4A). Due to these 
FigUre 4 | Quantification of T cell number, T cell proliferation, and dendritic cell number in wild-type (WT) vs. cathepsin e (ctse)−/− allogeneic 
hematopoietic stem cell transplantation (allo-scT) recipients. WT vs. Ctse−/− C57Bl/6 mice were used as SCT recipients. (a,B) Quantification of CD8+ cells in 
lymph nodes of Ctse−/− and WT recipients on day +16 after allo-SCT in the LP/J→C57BL/6 model. (c,D) In vivo proliferation assay with CFSE labeled Balb/C 
MHC-mismatched (c) or 129J miHA-mismatched (D) CD3+ lymphocytes. The percentage of proliferating CD3+ donor T cells is shown. (e–h) Analyses during 
established graft-versus-host disease at day +16 after allo-SCT in the LP/J→C57BL/6 model. (e,F) Quantification of CD11c+ cells in spleen and bone marrow from 
Ctse−/− vs. WT allo-SCT recipients. (g) Quantification of MHC II+ host cells in the spleen of Ctse−/− vs. WT allo-SCT recipients. (h) Quantification of CD86+ host cells 
in the spleen of Ctse−/− vs. WT allo-SCT recipients. Data were obtained with applying the markers of interest to the live cell gate. n = 5 animals per group and per 
experiment. Error bars indicate mean ± SEM, p-values were calculated using Wilcoxon–Mann–Whitney rank sum test.
FigUre 3 | histopathological scores and T cell infiltration is reduced in cathepsin e (ctse)−/− allogeneic hematopoietic stem cell transplantation 
(allo-scT) recipients. (a,D) Score of histopathological analysis of liver and colon sections at day +16 after allo-SCT in wild-type (WT) vs. Ctse−/− allo-SCT 
recipients. (B,e) Examples of H + E stainings of liver and colon sections from Ctse−/− vs. WT allo-SCT recipients. (c,F) Analysis of T cell infiltration into liver and 
colon at day +16 after allo-SCT, measured by labeled lymphocyte immunofluorescence area of total liver area or total colon mucosal area in WT and Ctse−/− allo-
SCT recipients at day +16. n = 5 for all experiments. For immunofluorescence T cell infiltration analysis, six pictures per animal were taken. Bright-field images were 
taken using a Motic BA410 microscope with a Moticam Pro 285B and the Motic Images Plus 2.0 software. The used objective was a Plan Fluar 20×/0.50. Error 
bars indicate mean ± SEM, p-values were calculated using Wilcoxon–Mann–Whitney rank sum test. Bar = 100 μm.
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results and because of the previously described role of Ctse on 
antigen presentation, we wanted to determine the impact of 
Ctse deficiency on proliferation of allogeneic donor T cells. 
Ctse KO C57BL/6 mice and WT littermates were conditioned 
with chemotherapy and CFSE-labeled, miHA-mismatched 
CD3+ lymphocytes from 129J donors or CD3+ lymphocytes 
from Balb/c (major MHC mismatch) were injected i.v. into the 
tail vein. Ninety-six hours later, cells were isolated from spleen 
FigUre 5 | reduced cD11c+ and cD8+ cell counts in graft-versus-host disease target organs of cathepsin e (ctse)-deficient allogeneic 
hematopoietic stem cell transplantation (allo-scT) recipients. (a,B) Analysis of CD11c-expressing cells in cryosections of Ctse−/− vs. wild-type(WT) allo-SCT 
recipients on day +16 after SCT in the LP/J→C57BL/6 model. (B) Representative images of CD11c IF labeling in liver of Ctse−/− vs. WT allo-SCT recipients.  
(c–F) Analysis of CD4+ or CD8+ T cell infiltration into colon and liver of Ctse−/− vs. WT allo-SCT recipients, measured by labeled lymphocyte immunofluorescence 
area of total liver area or total colon mucosal area. n = 5 animals per group and per experiment. Fluorescence images were taken using a Motic BA410 microscope 
with a Moticam Pro 285B and the Motic Images Plus 2.0 software. The used objective was a Plan Fluar 40×/0.75. Error bars indicate mean ± SEM, p-values were 
calculated using Wilcoxon–Mann–Whitney rank sum test. Bar = 50 μm.
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and lymph nodes for flow cytometric analyses. The proportion 
of proliferating T cells was not significantly different between 
Ctse-deficient recipients vs. WT recipients in both models, 
neither in percent of less CFSE-labeled T cells (counted as 
proliferating cells) compared to control CFSE labeled T cells 
(as shown, Figures 4C,D; Figures S5 and S6 in Supplementary 
Material) nor in the mean fluorescence index of CFSE positive 
cells in these assays (calculated by FlowJo software, data not 
shown). Furthermore, we found that Ctse deficiency of DCs 
had no significant impact on the in  vitro proliferation rate 
of allogeneic T cells in MLRs (Figure S4 in Supplementary 
Material). Taken together, we found in our model and assays no 
major impact of Ctse on the ability of DCs to induce alloactiva-
tion of donor T cells.
To further investigate the impact of Ctse deficiency of the 
allo-SCT recipient on host DCs, we analyzed DC numbers 
and activation status during GVHD in BM, lymph nodes, 
and spleen. We found no significant differences in DC counts 
between Ctse-deficient allo-SCT recipients vs. WT allo-SCT 
recipients in lymph nodes. However, there was a non-significant 
trend toward reduced CD11c+ DC numbers in BM and spleen 
(Figures 4E,F) as well as a trend toward lower MHCII expression 
on live cells and CD86 expression of Ctse-deficient DCs during 
GVHD (Figures  4G,H). Other activation markers, like CD40 
and CD80, were found to be expressed similar in Ctse-deficient 
vs. WT animals at day +16 post BMT (data not shown). Of note, 
at the day of analysis (day +16 post allo-SCT) around 60–70% of 
all cells in the investigated lymphoid organs were donor marker 
Ly9.1 negative.
The numbers of Tissue-infiltrating Dcs is 
reduced in livers of ctse-Deficient allo-
scT recipients during gVhD
Next, we were interested in tissue-infiltrating DCs during 
GVHD. For analyses, we chose liver and omitted colon because 
in colon CD11c expression is found on a substantial proportion 
of macrophages, which is a confounder (28). We used the LP/J 
(H2b)→C57BL/6 (H2b) model and found significantly less liver-
infiltrating CD11c+ cells in Ctse-deficient allo-SCT recipients vs. 
WT allo-SCT recipients (Figures 5A,B). In addition, we found 
reduced numbers of tissue-infiltrating CD8+ T cells in liver 
and colon of Ctse-deficient allo-SCT recipients during GVHD 
(Figures  5C,D). Again, CD4+ T cell infiltration into liver and 
colon was found to be only slightly reduced and was not statisti-
cally significant (Figures 5E,F).
The Motility of ctse-Deficient Dcs is 
impaired
In our experiments, the reduced DC counts in liver in Ctse−/− 
allo-SCT recipients during GVHD were striking. Importantly, 
overexpression of Ctse has been shown by different groups to 
increase the invasive and migratory capacity of cancer cells (24, 
29, 30), raising the possibility that Ctse is a positive regulator 
of cell motility. Additionally, it was shown by Chen et  al. (31) 
and Reichardt et  al. (32) that DC motility influences GVHD 
development. We therefore hypothesized that Ctse deficiency 
does have an influence on DC motility, thus leading to reduced 
migration of DCs to target organs and a lower degree of ti ssue 
FigUre 6 | cathepsin e (ctse)-deficient dendritic cells (Dcs) show impaired adhesion and invasion potential. (a) Experimental setup of determination of 
FITC-labeled DC (FITC+ CD11c+) migration to draining lymph nodes. Measurement was done 24 h after local application of irritant-solved FITC to the ear skin.  
(B) Quantification of FITC+ CD11c+ cells in the lymph nodes of Ctse+/+ (n = 11), Ctse+/− (n = 3), and Ctse−/− (n = 11) mice. (c) DC migration through a porous 
uncoated membrane in a Boyden Chamber (n = 3). (D–h) Adhesion and invasion was quantified by impedance measurements using the xCelligence system (ACEA) 
and plotted as Cell Index. (D) Representative adhesion measurement on collagen I coated surface. The slope between the time points a and b, where firm adhesion 
occurs, was further analyzed. (e) Quantification of DC adhesion on collagen I (n = 3). (F) Representative invasion assay through a layer of collagen I in presence of 
LPS in the upper well and CCL19 and CCL21 in the lower well. (g) Quantification of DC invasion through collagen I (1.73 mg/ml; n = 3), and (h) Matrigel™ (9 mg/
ml; n = 3). Error bars indicate mean ± SD, p-values were calculated using non-parametric Kruskal–Wallis ANOVA and a post hoc Mann–Whitney U-test (B), the 
two-sided two sample t-test (c) or two-sided one-sample t-test for the normalized data in panels (e,g,h).
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inflammation in Ctse-deficient allo-SCT recipients during 
GVHD.
Following our hypothesis, we analyzed DCs from Ctse−/− and 
WT animals for important motility characteristics of APCs. In an 
FITC ear paint assay (Figure 6A), we found a 60% reduction in 
FITC+ CD11c+ cell counts in the draining lymph nodes of Ctse−/− 
mice as compared to WT mice (Figure  6B). Interestingly, we 
(Figure 6C) and others could not show any significant difference 
in transwell migration of Ctse-deficient DCs compared to WT 
DCs following a chemoattractant stimulus (11). The movement 
of cells in vivo is, however, not solely dependent on their intrinsic 
motility but also depends on the ability to form contacts with 
the extracellular matrix (ECM) and to actively transmigrate 
through matrix-rich areas. While adhesion to ECM components 
is one important step in entering, for example, vascular struc-
tures, to migrate from the periphery to distant locations, like 
lymph nodes and other tissues in vivo, the second crucial step 
is transmigration through these ECM structures like the basal 
membrane of endo- and epithelial layers. Here, we could show 
that both steps in this process, the adhesion to (Figures 6D,E) 
FigUre 7 | analysis of el4 T cell lymphoma growth in untreated cathepsin e (ctse)-deficient mice vs. wild-type (WT) mice. C57Bl/6 WT or Ctse KO 
mice were injected intravenously with 1 × 106 luciferase-expressing EL4 tumor cells. (a) Schematic representation of the tumor model. (B) Survival curve of WT and 
Ctse−/− (Ctse KO) mice after EL4 lymphoma cell injection, statistical analysis was done using the Mantel–Cox log-rank test. (c) Average radiance data of WT and 
Ctse−/− mice after tumor cell injection. n = 12 per group. Error bars indicate mean ± SEM. Day 14 after tumor challenge p < 0.01; all other time points not 
significant. (D) Pictures of WT and Ctse−/− mice on day 14 after EL4 T cell lymphoma injection.
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and the transmigration through ECM substrates like collagen 
and matrigel (Figures 6F–H), were markedly reduced between 
40 and 80% in in vitro assays using Ctse-deficient DCs compared 
to WT DCs. We conclude that Ctse is involved in regulating the 
motility of DCs.
analysis of the impact of ctse Deficiency 
on Tumor growth
A possible role of Ctse in antitumor immunity has been suggested 
by others (33, 34). We therefore studied the role of Ctse in anti-
tumor responses in C57BL/6 WT mice vs. C57BL/6 Ctse−/− mice 
(Figure 7A). Mice were challenged intravenously with EL4 T cell 
lymphoma cells. We found no significant differences in tumor-
associated mortality and survival (Figure 7B). In bioluminescence 
imaging, we found no significant differences of tumor growth 
in Ctse−/− mice vs. WT mice at most time points (Figure  7C). 
However, at the earliest time point that we chose for imaging 
(day 14 after tumor challenge), tumor load was moderately, but 
significantly, higher in Ctse−/− mice vs. WT mice (Figure  7D). 
Taken together, our data argue against a major impact of Ctse on 
immunity against EL4 lymphoma.
DiscUssiOn
We found upregulation of Ctse in target organs during GVHD 
that was mainly caused by tissue infiltration of Ctse-expressing 
immune cells, such as CD11c+ cells. Our data, positively, 
connect to previous reports on increased Ctse activity in 
inflammatory and infectious diseases (14, 15). The restriction 
of Ctse expression to immune cells is in line with previous 
publications showing that Ctse is predominantly expressed in 
antigen-presenting cells (6, 8). Furthermore, it was shown that 
Ctse was not expressed in T cells and we found its deficiency on 
the donor side had no significant influence on GVHD, suggest-
ing that Ctse has no important direct impact on alloactivation of 
T cells.
Using Ctse−/− and WT littermate transgenic mice, we found 
that Ctse deficiency in allo-SCT recipients ameliorates acute 
GVHD. In histology, the effect of Ctse deficiency on target 
organ histology was stronger in liver, as compared with colon 
(Figure 3). In contrast, when we used Ctse−/− and WT littermate 
transgenic mice as allo-SCT donors, we found no significant 
impact on GVHD. These results demonstrate that the Ctse 
deficiency on the recipient side is involved in GVHD regulation. 
Our data provide novel evidence on the significant biologic role 
of Ctse in alloreactivity and inflammation. This information 
adds to the existing evidence on the important role of molecules 
that are involved in sensing and processing of bacterial peptides, 
such as nod-like-receptors and toll like receptors (2). To our 
knowledge, this is the first report on the role of Ctse during 
allo-SCT. One previous report associated Cathepsin S (Ctss), a 
lysosomal cysteine protease, with the development of GVHD. 
Ctss mRNA expression and activity was upregulated after 
allo-SCT. However, the pharmacologic inhibition of Ctss led to 
increased GVHD, possibly because of cross presentation to MHC 
class I (35). Our data on Ctse during GVHD are in line with 
our previous publication on reduced inflammation in asthma 
models in Ctse−/− mice (25). However, our findings are in some 
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disagreement to in  vitro investigations with an independently 
generated Ctse−/− mouse showing that Ctse deletion reduced 
OVA-stimulated T cell activation by Ctse−/− macrophages but 
enhanced T cell response by Ctse−/− DCs (11). These discrep-
ancies might be due to variable cell type- and antigen-specific 
roles of proteases in antigen presentation, and also highlights 
the importance of systematic and careful dissection of the role 
of Ctse for DC function in complex in vivo systems such as our 
GVHD model.
To investigate the mechanism how Ctse influences GVHD, we 
were first interested in the ability of antigen-presenting cells, such 
as DCs, to induce allogeneic T cell proliferation. In MHC-matched 
and MHC-mismatched models, we found that Ctse deficiency 
in antigen-presenting cells had no major impact on alloactiva-
tion of WT donor T cells in vivo and in vitro. Although robust 
data exist showing that Ctse has important functions in antigen 
presentation, our data argue against a major biologic relevance of 
Ctse-mediated antigen presentation during GVHD. In search for 
alternative mechanisms how Ctse regulates GVHD, we became 
interested in DC motility because of the significantly reduced 
DC numbers we found during hepatic GVHD in Ctse-deficient 
allo-SCT recipients. We demonstrated that Ctse deficiency results 
in profoundly impaired DC motility and adhesion to and migra-
tion through ECM. These results might be the explanation for the 
reduced DC numbers in GVHD target organs of Ctse-deficient 
mice compared to WT animals. To our knowledge, this is the first 
report on the impact of cathepsin proteases during DC motility. Of 
note, we found no significant differences in DC numbers in lymph 
nodes of Ctse-deficient allo-SCT recipients vs. WT allo-SCT 
recipients. Based on previous knowledge and our experimental 
data, we are currently unable to provide a mechanistic explana-
tion of this discrepancy between DC numbers lymph nodes and 
the liver. Another limitation of our study is, that we were unable 
to prove, that the observed effects are mediated by Ctse activity in 
DCs. It is also possible that Ctse-mediated effects in other recipi-
ent cell types, e.g., in macrophages, may have contributed to the 
observed effects. Others (31, 32) have shown that either miR-155 
deficiency in the recipient DC compartment or rapamycin-
treated host DCs led to impaired GVHD development. In both 
studies, the motility of DCs was shown to be affected as well as 
the expression of surface receptors and cytokine expression in the 
investigated DC populations. In addition, it has previously been 
demonstrated that Ctse expression in cancer cells is associated 
with increased invasiveness, linking Ctse to cell motility (24, 29, 
30). Others could show decreased DC motility in mice deficient 
for syndecan-4 or heparanase (36, 37). Similar to Ctse, both 
proteins are related to ECM interaction and degradation, and in 
both cases, reduced DC motility led to reduced inflammation in 
the respective models. Regarding clinical development, Ctse is a 
feasible target for small molecule inhibitors, like pepstatin A (38) 
or other aspartic protease inhibitors (39). Taken together, previ-
ous studies provided evidence for the biologic significance of DC 
motility. Our findings on reduced DC motility in Ctse-deficient 
mice provide a possible link between microbial products and DC 
motility.
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